



MiRNA-Based Therapeutics in Cancer

Guest Editors:

Dr. Marilena V. Iorio

Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy

Dr. Orazio Fortunato

Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy

Deadline for manuscript
submissions:

closed (25 October 2021)

Message from the Guest Editors

MicroRNAs (miRNAs) play an active role in the modulation of cellular physiological processes such as apoptosis, cell-cycle control, cell proliferation, DNA repair, and metabolism. Increasing evidence has revealed a deregulation of miRNA levels in cancer and a negative regulation of gene and protein expression by acting as oncogenes or tumor suppressors. Several studies both in vitro and in vivo have demonstrated that correction of miRNAs' alteration in cancer cells could revert their malignant phenotypes.

This Special Issue focuses on miRNA-based therapeutic strategies for cancer treatment, a topic that has raised extreme interest in the scientific community in recent years. Experimental approaches such as inhibition of oncogenic miRNAs or replacement of tumor suppressors both in vitro and in vivo will be included. New approaches using viral or nonviral agents to achieve miRNA systemic delivery considering safety and potential off-target effects will be discussed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com